Skip to main content

Gynecologic Oncology Clinical Trials

The Division of Gynecologic Oncology has one of the largest Clinical Trial Research Programs in Northern California and is on the forefront of translational research in gynecologic cancers. Through the collaborative work of our providers, research team and other UCSF staff, we offer a wide variety of clinical trials that provide women with gynecologic cancers access to cutting edge investigational therapies and treatment methods. Our practice serves as a regional research hub which attracts patients from across California seeking out clinical trials. Additionally, we are a voting member of the national Cooperative Group NRG Oncology, an interdisciplinary research organization dedicated to improving the survival and quality of life of cancer patients through research, where we help to shape Gynecologic Oncology care on a national and global level. We are excited to continue to grow our Clinical Research Program by adding additional staff and expanding our trial portfolio, with the goal of being able to provide any woman with gynecologic cancer interested in participating in a clinical trial access to potentially life-saving therapy.

The following trials are currently open to accrual:

Cooperative Group Trials

  • NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
    • Now open to accrual
    • NCT03914612
  • NRG GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
    • Now open to accrual
    • NCT04095364
  • NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
    • Now open to accrual
    • NCT04251052
  • NRG-GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer
    • Now open to accrual
    • NCT02839707

Industry Trials

  • GOG-3026: A Phase II Trial of Ribociclib (LEE011) plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
    • Now open to accrual
    • NCT03673124
  • GOG-3028: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (anti–PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) – RaPiDS
    • Now open to accrual
    • NCT03894215
  • GOG-3045 MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
    • Now open to accrual
    • NCT04209855
  • GOG-3041: DUO-E A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
    • Now open to accrual
    • NCT04269200




If you would like more information regarding our Gynecologic Oncology Trials at UCSF, please email our team at [email protected].

For the most recent list of clinical trials, please visit: